Xolair denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for xolair are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Xolair (omalizumab) as Non-Formulary

A non-formulary denial for Xolair means your specific UHC plan does not include Xolair at a covered tier, or places it at a specialty tier requiring additional approval. Xolair is a specialty biologic and is subject to pharmacy or medical-benefit formulary management depending on how it is administered (self-injected vs. in-office). Formulary placement varies by plan — the same insurer may cover Xolair on some plans and not others. However, most plans are required to offer a formulary-exception process, and because Xolair has multiple FDA-approved indications with no direct therapeutic equivalent for all patients, exceptions are routinely granted with the right documentation.

## Your Appeal Rights

• Formulary exception / internal appeal (ERISA §503 / ACA): File a formulary-exception request alongside a formal internal appeal. These can be submitted together. The plan must have an exception process.
• External review (ACA §2719): If the exception and internal appeal are denied, independent external review is available. File within the four-month window from the final internal denial.
• Expedited review: Request expedited processing if the patient has uncontrolled allergic disease and delay would be harmful.

## Documentation to Gather

1. Diagnosis confirmation — chart documentation of the specific FDA-approved indication (allergic asthma, CIU/CSU, nasal polyps, or food allergy per current label). 2. Formulary-alternative evaluation — for each formulary-covered drug UHC identifies as an alternative, the prescriber must document whether it was tried, the outcome, and — if not tried — the clinical reason it is not appropriate for this patient. For Xolair's unique IgE-targeting mechanism, there may be no formulary biologic with the same mechanism. 3. Prescriber medical-necessity and exception letter — signed, individualized, explaining why Xolair is required and why formulary alternatives are not clinically equivalent for this patient. 4. FDA prescribing label — confirm the approved indication and attach. 5. UHC formulary-exception criteria — request the criteria in writing before filing; address each listed requirement explicitly. 6. Benefit design clarification — confirm whether Xolair is covered under the pharmacy benefit or the medical benefit on this plan; if the medical-benefit pathway is available (in-office administration), it may have a different formulary.

## Criteria-Mapping Structure

| UHC Formulary-Exception Requirement | Patient-Specific Response | |---|---| | FDA-approved indication documented | FDA label + chart diagnosis notes | | Formulary alternative(s) tried or contraindicated | Trial history or prescriber contraindication letter | | Clinical necessity for Xolair specifically | Prescriber exception letter, mechanism discussion | | Severity of condition documented | Clinical notes, validated severity measures |

If Xolair is covered under the medical benefit (in-office injection) but not the pharmacy benefit (self-injection), the prescriber and patient should discuss whether in-office administration is feasible — this may resolve the non-formulary issue without an appeal.